NCT03332212View on ClinicalTrials.gov

A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take Empagliflozin

PHASE3CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

May 21, 2020

Study Completion Date

May 28, 2020

Conditions
Heart Failure
Interventions
DRUG

Empagliflozin

12 weeks

DRUG

Placebo

12 Weeks

Trial Locations (1)

OX3 9DU

John Radcliffe Hospital, Oxford

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Boehringer Ingelheim

INDUSTRY

NCT03332212 - A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take Empagliflozin | Biotech Hunter | Biotech Hunter